CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy

Description

Anxiety-, obsessive-compulsive and trauma- and stressor-related disorders reflect a significant public health problem. This study is designed to evaluate the predictive power of a novel biomarker based on a CO2 challenge, thus addressing the central question "can this easy-to-administer assay aid clinicians in deciding whether or not to initiate exposure-based therapy?"

Conditions

Obsessive-Compulsive Disorder, Post Traumatic Stress Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder

Talk to us

Study Overview

On this page

Study Details

Study overview

Anxiety-, obsessive-compulsive and trauma- and stressor-related disorders reflect a significant public health problem. This study is designed to evaluate the predictive power of a novel biomarker based on a CO2 challenge, thus addressing the central question "can this easy-to-administer assay aid clinicians in deciding whether or not to initiate exposure-based therapy?"

Carbon Dioxide (CO2) Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy

CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy

Condition
Obsessive-Compulsive Disorder
Intervention / Treatment

-

Contacts and Locations

Boston

Boston University, Boston, Massachusetts, United States, 02215

Austin

The University of Texas at Austin, Austin, Texas, United States, 78712

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * A primary DSM-5 diagnosis of panic disorder (with or without an agoraphobia diagnosis), social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder, or post-traumatic stress disorder as assessed by the Structured Clinical Interview for the DSM-5 (SCID-5)
  • * A score of 8 or greater on the Overall Anxiety Severity and Impairment Scale (OASIS)
  • * Ages 18 to 70
  • * Willingness and ability to provide informed consent and comply with the requirements of the study protocol.
  • * Proficiency in English (because assessment instruments have only been validated in English)
  • * A lifetime history of bipolar or psychotic disorders, substance use disorders (other than nicotine) or eating disorder in the past 6 months; serious cognitive impairment.
  • * Active suicidal ideation with at least some intent to act with or without specific plan (a rating of 4 for suicidal ideation on the Columbia-Suicide Severity Rating Scale) or suicidal behaviors (actual attempt, interrupted attempt, aborted or self-interrupted attempt, or preparatory acts or behavior) within the past 6 months.
  • * Medical conditions contraindicating CO2 inhalation or hyperventilation challenge (e.g., cardiac arrhythmia, cardiac failure, asthma, lung fibrosis, high blood pressure, epilepsy, or stroke).
  • * Pregnancy or lactation
  • * Ongoing psychotherapy directed toward the primary disorder.
  • * Pharmacological treatment started within 8 weeks prior to the screen (patients "stable" on their medication regimen will be included and their medication status will be included as a variable in the model)

Ages Eligible for Study

18 Years to 70 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Texas at Austin,

Jasper Smits, Ph.D., PRINCIPAL_INVESTIGATOR, The University of Texas at Austin

Michael Otto, Ph.D., PRINCIPAL_INVESTIGATOR, Boston University

Study Record Dates

2027-02-28